A Long-Term, Follow-On Safety Study of Four Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons

Inclusion Criteria Concurrent Medication: Allowed: Chemoprophylaxis for Pneumocystis carinii, candida, and mycobacteria. Acyclovir for acute treatment of herpes. Exclusion Criteria Concurrent Medication: Excluded: Antiretroviral agents, including ddI, ddC, AZT, and d4T. Immunosuppressive agents. Investigational HIV drugs/therapies including vaccines. Interferon or other immunomodulating agents. Corticosteroids (other than topical). Megestrol acetate. Agents known to cause neutropenia. Ganciclovir. Cytotoxic chemotherapy. Concurrent Treatment: Excluded: Radiation therapy. Patients with the following prior conditions are excluded: Poor compliance (less than 80 percent of drug taken) on the Phase I protocol (FDA 234A or FDA 234B). Missed more than one clinic visit on the Phase I protocol. Prior Medication: Excluded: Acyclovir as prophylaxis for herpes within 48 hours prior to study entry. Patients meet the following criteria: Successful completion of short-term therapy with vesnarinone on FDA 234A or FDA 234B. Active illicit drug abuse.